Americans have waited long enough, and now real relief from sky-high prescription drug prices is finally here. Recently, President Donald J. Trump signed a landmark Executive Order to end the decades-long injustice that has forced American families — especially Hispanic households — to pay more for lifesaving medications than almost anyone else in the world.
Hispanics, who are more likely to be uninsured or underinsured compared to other groups, are disproportionately burdened by high out-of-pocket prescription costs. In fact, according to the CDC, nearly one in four Hispanic adults report not taking prescribed medications due to cost, compared to just 13% of non-Hispanic White adults. This Executive Order directly addresses that disparity by demanding lower drug prices and making medications more affordable and accessible for millions of working families across the country.
This bold order reaffirms the President’s unwavering commitment to putting American patients first by stopping foreign free-riding, crushing the stranglehold of pharmaceutical middlemen, and bringing fairness back to a rigged system.
Under President Trump’s leadership, America is no longer the world’s piggy bank for pharmaceutical giants and socialized healthcare systems abroad. This Executive Order directs the U.S. Trade Representative and Secretary of Commerce to hold foreign nations accountable for the unfair practices that underpay for prescription drugs and undermine lifesaving drug development. In essence, Americans — who fund the bulk of pharmaceutical innovation through our taxpayer dollars and higher prices — have been subsidizing socialism abroad. No more.
For many Americans across the U.S., especially those economically impacted by high healthcare costs, this Executive Order is a game changer. Families working long hours, often balancing multiple jobs, should not have to choose between buying insulin for their children or groceries for the week. President Trump’s directive ensures that low-income patients, seniors, and working-class Americans will now have direct access to the same steep discounts that pharmaceutical companies give to patients overseas through government-negotiated prices.
That means bypassing the costly middlemen and securing medicines at “most-favored-nation” prices that reflect the best deal given to any other country in the world. If drug manufacturers refuse, the Order empowers the Secretary of Health and Human Services Robert F. Kennedy Jr. to act decisively: impose these pricing standards through regulation and take additional aggressive steps to drive costs down. This is what America First leadership looks like.
Let’s not forget: President Trump has been down this road before. In his first term, he introduced bold reforms to ensure that Medicare would no longer overpay pharmaceutical companies — specifically, by requiring that prices for Medicare-covered drugs be no higher than those paid in comparable countries. These common-sense measures were rescinded by the Biden-Harris Administration before they could take effect. The result? A so-called “victory” for Medicare that actually left American taxpayers and seniors paying an average of 78% more for prescription drugs than patients in eleven other advanced nations. That’s not a win — it’s a disgrace.
Now, in his second term, President Trump is finishing what he started. This new action builds upon earlier victories, including transparency in hospital pricing, the push for generics and biosimilars, and expanded drug importation options. These initiatives are part of a comprehensive, America First healthcare agenda focused not on enriching bureaucracy, but on empowering patients.
For those disproportionately affected by chronic conditions like diabetes, hypertension, and asthma, this move provides tangible economic relief. It ensures families can access the medicine they need to stay healthy. It means hardworking Americans can afford care without risking financial ruin. And it signals that forgotten communities are no longer overlooked — they are being heard and prioritized.
We should also be clear: this isn’t just good policy. It’s great politics. President Trump is showing the American people that he’s not afraid to stand up to entrenched interests to deliver real results. He’s not beholden to Big Pharma, nor is he willing to play nice with foreign governments who exploit our generosity while we suffer at home.
In an era where politicians too often offer empty promises and soaring rhetoric, President Trump delivers. His commitment to reforming healthcare pricing is not just about economics—it’s about justice. And make no mistake: justice is exactly what millions of Americans, especially those in underserved communities, have been demanding for years.
President Trump said it best: “Our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory.” That ends now.
This is more than an Executive Order. It’s a promise fulfilled, a burden lifted, and another bold move in President Trump’s mission to restore prosperity, fairness, and dignity to the American people.
* * *
Bobby Jindal is the former Governor of Louisiana and Chair of the Center for a Healthy America at America First Policy Institute.
Jorge Martinez is National Director for Hispanic Outreach for America First Policy Institute. He previously served as press secretary for the U.S. Department of Justice.

Continue reading this exclusive article and join the conversation, plus watch free videos on DW+
Already a member?